Recreational Use, Analysis and Toxicity of Tryptamines
This comprehensive review (2015) summarizes the chemical characterization, pharmacology, and toxicity of New Psychoactive Substances from the published literature, as well as information gathered from non-peer-reviewed sources, such as drug forums. They provide an overview of useful information, such as reported death cases, for public health workers.
Authors
- Tittarelli, R.
- Mannocchi, G.
- Pantano, F.
Published
Abstract
Introduction
The definition New psychoactive substances (NPS) refers to emerging drugs whose chemical structures are similar to other psychoactive compounds but not identical, representing a “legal” alternative to internationally controlled drugs. There are many categories of NPS, such as synthetic cannabinoids, synthetic cathinones, phenylethylamines, piperazines, ketamine derivatives and tryptamines. Tryptamines are naturally occurring compounds, which can derive from the amino acid tryptophan by several biosynthetic pathways: their structure is a combination of a benzene ring and a pyrrole ring, with the addition of a 2-carbon side chain. Tryptamines include serotonin and melatonin as well as other compounds known for their hallucinogenic properties, such as psilocybin in ‘Magic mushrooms’ and dimethyltryptamine (DMT) in Ayahuasca brews.
Aim
To review the scientific literature regarding tryptamines and their derivatives, providing a summary of all the available information about the structure of these compounds, their effects in relationship with the routes of administration, their pharmacology and toxicity, including articles reporting cases of death related to intake of these substances.
Methods
A comprehensive review of the published scientific literature was performed, using also non peer-reviewed information sources, such as books, government publications and drug user web fora.
Conclusions
Information from Internet and from published scientific literature, organized in the way we proposed in this review, provides an effective tool for specialists facing the emerging NPS threat to public health and public security, including the personnel working in Emergency Department.
Research Summary of 'Recreational Use, Analysis and Toxicity of Tryptamines'
Introduction
New psychoactive substances (NPS) comprise a broad and evolving set of compounds whose structures are similar to controlled drugs but differ enough to evade scheduling, and they are often marketed as "research chemicals", "incense" or other benign products. Tryptamines form one chemical class of NPS as well as a group of naturally occurring signalling molecules (notably serotonin and melatonin) and classical hallucinogens (for example psilocybin and DMT). Earlier research has established that small structural changes to the tryptamine core strongly influence receptor binding, pharmacology and subjective effects, and that many tryptamines are not detected by routine toxicology screens used in emergency settings. Tittarelli and colleagues set out to collate and organise available information on tryptamines and their derivatives, focusing on chemical classification, structure–activity relationships, routes of administration, pharmacology, reported effects (including user reports), toxicology, documented emergency-room and coronial case reports, fatalities, and analytical methods for detection. The study is presented as a comprehensive literature review that incorporates peer-reviewed publications together with non–peer-reviewed sources such as books, government reports and online drug-user fora, with the aim of producing a practical reference for clinicians, forensic scientists and public-health professionals.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Topics
- APA Citation
Tittarelli, R., Mannocchi, G., Pantano, F., & Romolo, F. (2015). Recreational Use, Analysis and Toxicity of Tryptamines. Current Neuropharmacology, 13(1), 26-46. https://doi.org/10.2174/1570159x13666141210222409
References (7)
Papers cited by this study that are also in Blossom
Fantegrossi, W. E., Murnane, K. S., Reissig, C. J. · Biochemical Pharmacology (2007)
Ray, T. S. · PLOS ONE (2010)
Gable, R. S. · Addiction (2006)
Grof, S., Soskin, R. A., Richards, W. A. et al. · Pharmacopsychiatry (1973)
Nichols, D. E. · Pharmacology and Therapeutics (2004)
Hasler, F., Grimberg, U., Benz, M. A. et al. · Psychopharmacology (2004)
Shen, H. W., Jiang, X. L., Winter, J. C. et al. · Current Drug Metabolism (2010)
Cited By (9)
Papers in Blossom that reference this study
Puigseslloses, P., Nadal-Gratacós, N., Ketsela, G. et al. · Molecular Psychiatry (2024)
Barker, S. A. · Psychopharmacology (2022)
Catalani, V., Corkery, J. M., Guirguis, A. et al. · European Neuropsychopharmacology (2021)
Klein, A. K., Chatha, M., Laskowski, L. J. et al. · ACS Pharmacology and Translational Science (2020)
Palamar, J. J., Acosta, P. · Human Psychopharmacology (2020)
Dos Santos, R. G., Hallak, J. E., Bouso, J. C. · Therapeutic Advances in Psychopharmacology (2017)
Dinis-Oliveira, R. J. · Drug Metabolism Reviews (2017)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Rickli, A., Luethi, D., Reinisch, J. et al. · Neuropharmacology (2015)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.